Abstract
Optic neuritis (ON) is inflammation of the optic nerve and is the most common type of optic neuropathy. There is a strong association between ON and multiple sclerosis (MS), an acute inflammatory demyelinating syndrome of the central nervous system (CNS). A large number of etiological factors have been identified for ON including genetic susceptibility, smoking, exposure to the Epstein–Barr virus (EBV), and low exposure to sunlight. And the pathology of ON continues to be clarified with the advances in medicine and clinical peripheral devices. Since ON can cause severe visual loss, it draws much attention to detect the disease in early stage and finding a treatment that will restore visual function. In this chapter, the latest progress regarding the noninvasive detection methods for ON is summarized and current understanding of mechanisms underlying ON is reviewed, with references to MS. Lastly, existing drugs and chemicals that were developed for other therapeutic purposes are discussed as potential treatment strategies for ON.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Handel AE, Williamson AJ, Disanto G et al (2010) An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS One. doi:10.1371/journal.pone.0012496
Islam T, Gauderman WJ, Cozen W et al (2007) Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins. Neurology 69:381–388
Miller D, Barkhof F, Montalban X et al (2005) Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 4:281–288
Frohman EM, Fujimoto JG, Frohman TC et al (2008) Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol 4:664–675
Optic Neuritis Study Group (2008) Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 65:727–732. doi:10.1001/archneur.65.6.727
Marques IB, Matias F, Silva ED et al (2013) Risk of multiple sclerosis after optic neuritis in patients with normal baseline brain MRI. J Clin Neurosci. doi:10.1016/j.jocn.2013.06.013
Mehrotra A, Jaffery N, Saxena R et al (2007) Comparative evaluation of megadose methylprednisolone with dexamethasone for treatment of primary typical optic neuritis. Indian J Ophthalmol 55:355–359
Menon V, Saxena R, Misra R et al (2011) Management of optic neuritis. Indian J Ophthalmol 59:117–122. doi:10.4103/0301-4738.77020
Balcer LJ (2006) Clinical practice. Optic neuritis. N Engl J Med 354:1273–1280
Tullman MJ, Lublin FD, Miller AE (2002) Immunotherapy of multiple sclerosis-current practice and future directions. J Rehabil Res Dev 39:273–285
Wingerchuk DM, Lennon VA, Lucchinetti CF et al (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6:805–815
Lennon VA, Kryzer TJ, Pittock SJ et al (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473–477
Nielsen S, Nagelhus EA, Amiry-Moghaddam M et al (1997) Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci 17:171–180
Ratelade J, Zhang H, Saadoun S et al (2012) Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathol 123:861–872. doi:10.1007/s00401-012-0986-4
Watanabe S, Nakashima I, Misu T et al (2007) Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 13:128–132
Wang KC, Wang SJ, Lee CL et al (2011) The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci 18:43–46. doi:10.1016/j.jocn.2010.05.030
Cree BA, Lamb S, Morgan K et al (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64:1270–1272
Garvin MK, Abràmoff MD, Wu X et al (2009) Automated 3-D intraretinal layer segmentation of macular spectral-domain optical coherence tomography images. IEEE Trans Med Imaging 28:1436–1447. doi:10.1109/TMI.2009.2016958
Sakata LM, Deleon-Ortega J, Sakata V et al (2009) Optical coherence tomography of the retina and optic nerve – a review. Clin Experiment Ophthalmol 37:90–99. doi:10.1111/j.1442-9071.2009.02015.x
Frohman EM, Fujimoto JG, Frohman TC et al (2008) Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol 4:664–675. doi:10.1038/ncpneuro0950
Monteiro ML, Fernandes DB, Apóstolos-Pereira SL et al (2012) Quantification of retinal neural loss in patients with neuromyelitis optica and multiple sclerosis with or without optic neuritis using Fourier-domain optical coherence tomography. Invest Ophthalmol Vis Sci 53:3959–3966. doi:10.1167/iovs.11-9324
Schneider E, Zimmermann H, Oberwahrenbrock T et al (2013) Optical coherence tomography reveals distinct patterns of retinal damage in neuromyelitis optica and multiple sclerosis. PLoS One 8:e66151
Sandberg MA, Ariel M (1977) A hand-held two channel stimulator ophthalmoscope. Arch Ophthalmol 95:1881–1882
Jones R, King–Smith PE, Loffing DH et al (1986) Stray light contributions to the focal electroretinogram (ERG). Clin Vis Sci 1:153–160
Sutter EE (1991) The fast m-transform: a fast computation of cross-correlations with binary m-sequences. Society Ind Appl Math 20:686–694
Sutter EE, Tran D (1992) The field topography of ERG components in man, I: the photopic luminance response. Vision Res 32:433–446
Hood DC, Seiple W, Holopigian K et al (1997) A comparison of the components of the multifocal and full-field ERGs. Vis Neurosci 14:533–544
Hasegawa S, Ohshima A, Hayakawa Y et al (2001) Multifocal electroretinograms in patients with branch retinal artery occlusion. Invest Ophthalmol Vis Sci 42:298–304
Sutter EE, Bearse MA Jr (1999) The optic nerve head component of the human ERG. Vision Res 39:419–436
Ball SL, Petry HM (2000) Noninvasive assessment of retinal function in rats using multifocal electroretinography. Invest Ophthalmol Vis Sci 41:610–617
Harada T, Harada C, Nakamura K et al (2007) The potential role of glutamate transporters in the pathogenesis of normal tension glaucoma. J Clin Invest 117:1763–1770
Guo X, Harada C, Namekata K et al (2010) Regulation of the severity of neuroinflammation and demyelination by TLR-ASK1-p38 pathway. EMBO Mol Med 2:504–515. doi:10.1002/emmm.201000103
Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197–216
Beutler B, Rietschel ET (2003) Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 3:169–176
Akira S, Takeda K, Kaisho T (2001) Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2:675–680
Ponomarev ED, Shriver LP, Maresz K et al (2005) Microglial cell activation and proliferation precedes the onset of CNS autoimmunity. J Neurosci Res 81:374–389
Tanuma N, Sakuma H, Sasaki A et al (2006) Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. Acta Neuropathol 112:195–204
Nair A, Frederick TJ, Miller SD (2008) Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci 65:2702–2720. doi:10.1007/s00018-008-8059-5
Fujihara K (2011) Neuromyelitis optica and astrocytic damage in its pathogenesis. J Neurol Sci 306:183–187. doi:10.1016/j.jns.2011.02.018
Hinson SR, Romero MF, Popescu BF et al (2012) Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A 109:1245–1250. doi:10.1073/pnas.1109980108
Farez MF, Quintana FJ, Gandhi R et al (2009) Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immunol 10:958–964. doi:10.1038/ni.1775
Kang Z, Altuntas CZ, Gulen MF et al (2010) Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity 32:414–425. doi:10.1016/j.immuni.2010.03.004
Skripuletz T, Bussmann JH, Gudi V et al (2010) Cerebellar cortical demyelination in the murine cuprizone model. Brain Pathol 20:301–312. doi:10.1111/j.1750-3639.2009.00271.x
Goritz C, Dias DO, Tomilin N et al (2011) A pericyte origin of spinal cord scar tissue. Science 333:238–242. doi:10.1126/science.1203165
Silver J, Miller JH (2004) Regeneration beyond the glial scar. Nat Rev Neurosci 5:146–156
Kuhlmann T, Lingfeld G, Bitsch A et al (2002) Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125:2202–2212
Lucchinetti C, Brück W, Parisi J et al (1999) A quantitative analysis of oligodendrocytes in multiple sclerosis lesions: a study of 113 cases. Brain 122:2279–2295
Merrill JE, Zimmerman RP (1991) Natural and induced cytotoxicity of oligodendrocytes by microglia is inhibitable by TGFβ. Glia 4:327–331
Peterson JW, Bö L, Mörk S et al (2002) VCAM-1-positive microglia target oligodendrocytes at the border of multiple sclerosis lesions. J Neuropathol Exp Neurol 61:539–546
Rasmussen S, Wang Y, Kivisäkk P et al (2007) Persistent activation of microglia is associated with neuronal dysfunction of callosal projecting pathways and multiple sclerosis-like lesions in relapsing–remitting experimental autoimmune encephalomyelitis. Brain 130:2816–2829
Heppner FL, Greter M, Marino D et al (2005) Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med 11:146–152
Ralay Ranaivo H, Craft JM, Hu W et al (2006) Glia as a therapeutic target: selective suppression of human amyloid-β-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci 26:662–670
Guo X, Nakamura K, Kohyama K et al (2007) Inhibition of glial cell activation ameliorates the severity of experimental autoimmune encephalomyelitis. Neurosci Res 59:457–466
Sloka S, Metz LM, Hader W et al (2013) Reduction of microglial activity in a model of multiple sclerosis by dipyridamole. J Neuroinflammation 10:89. doi:10.1186/1742-2094-10-89
Yong VW, Wells J, Giuliani F et al (2004) The promise of minocycline in neurology. Lancet Neurol 3:744–751
Metz LM, Li D, Traboulsee A, GA/Minocycline Study Investigators et al (2009) Glatiramer acetate in combination with minocycline in patients with relapsing–remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial. Mult Scler 15:1183–1194. doi:10.1177/1352458509106779
Ichijo H, Nishida E, Irie K et al (1997) Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275:90–94
Chiang E, Dang O, Anderson K et al (2006) Cutting edge: apoptosis-regulating signal kinase 1 is required for reactive oxygen species-mediated activation of IFN regulatory factor 3 by lipopolysaccharide. J Immunol 176:5720–5724
Matsuzawa A, Saegusa K, Noguchi T et al (2005) ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat Immunol 6:587–592
Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4:499–511
Harada C, Nakamura K, Namekata K et al (2006) Role of apoptosis signal-regulating kinase 1 in stress-induced neural cell apoptosis in vivo. Am J Pathol 168:261–269
Steinman L (2004) Immune therapy for autoimmune diseases. Science 305:212–216
Paul SM, Mytelka DS, Dunwiddie CT et al (2010) How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 9:203–214. doi:10.1038/nrd3078
Gilgun-Sherki Y, Melamed E, Offen D (2004) The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 251:261–268
Kizelsztein P, Ovadia H, Garbuzenko O et al (2009) Pegylated nanoliposomes remote-loaded with the antioxidant tempamine ameliorate experimental autoimmune encephalomyelitis. J Neuroimmunol 213:20–25. doi:10.1016/j.jneuroim.2009.05.019
Mohamed A, Waris HM, Ramadan H et al (2009) Amelioration of chronic relapsing experimental autoimmune encephalomyelitis (cr-eae) using thymoquinone. Biomed Sci Instrum 45:274–279
Qi X, Lewin AS, Sun L et al (2007) Suppression of mitochondrial oxidative stress provides long-term neuroprotection in experimental optic neuritis. Invest Ophthalmol Vis Sci 48:681–691
Ooie T, Takahashi N, Saikawa T et al (2001) Single oral dose of geranylgeranylacetone induces heatshock protein 72 and renders protection against ischemia/reperfusion injury in rat heart. Circulation 104:1837–1843
Katsuno M, Sang C, Adachi H et al (2005) Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc Natl Acad Sci USA 102:16801–16806
Harada C, Nakamura K, Guo X et al (2007) Neuroprotective effect of geranylgeranylacetone against ischemia-induced retinal injury. Mol Vis 13:1601–1607
Igarashi K, Kashiwagi K (2010) Modulation of cellular function by polyamines. Int J Biochem Cell Biol 42:39–51. doi:10.1016/j.biocel.2009.07.009
Deng K, He H, Qiu J et al (2009) Increased synthesis of spermidine as a result of upregulation of arginase I promotes axonal regeneration in culture and in vivo. J Neurosci 29:9545–9552. doi:10.1523/JNEUROSCI.1175-09.2009
Rider JE, Hacker A, Mackintosh CA et al (2007) Spermine and spermidine mediate protection against oxidative damage caused by hydrogen peroxide. Amino Acids 33:231–240
Eisenberg T, Knauer H, Schauer A et al (2009) Induction of autophagy by spermidine promotes longevity. Nat Cell Biol 11:1305–1314. doi:10.1038/ncb233
Guo X, Harada C, Namekata K et al (2009) Effect of geranylgeranylacetone on optic neuritis in experimental autoimmune encephalomyelitis. Neurosci Lett 462:281–285. doi:10.1016/j.neulet.2009.07.028
Guo X, Harada C, Namekata K et al (2011) Spermidine alleviates severity of murine experimental autoimmune encephalomyelitis. Invest Ophthalmol Vis Sci 52:2696–2703. doi:10.1167/iovs.10-6015
Park HS, Cho SG, Kim CK et al (2002) Heat shock protein hsp72 is a negative regulator of apoptosis signal-regulating kinase 1. Mol Cell Biol 22:7721–7730
Franklin RJ, Ffrench-Constant C (2008) Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 9:839–855. doi:10.1038/nrn2480
Kremer D, Aktas O, Hartung HP et al (2011) The complex world of oligodendroglial differentiation inhibitors. Ann Neurol 69:602–618. doi:10.1002/ana.22415
Chang A, Tourtellotte WW, Rudick R et al (2002) Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 346:165–173
Kuhlmann T, Miron V, Cui Q et al (2008) Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 131:1749–1758. doi:10.1093/brain/awn096
Deshmukh VA, Tardif V, Lyssiotis CA et al (2013) A regenerative approach to the treatment of multiple sclerosis. Nature 502:327–332. doi:10.1038/nature12647
Burgyone K, Aduri K, Ananth J et al (2004) The use of antiparkinsonian agents in the management of drug-induced extrapyramidal symptoms. Curr Pharm Des 10:2239–2248
Arnett HA, Fancy SP, Alberta JA et al (2004) bHLH transcription factor Olig1 is required to repair demyelinated lesions in the CNS. Science 306:2111–2115
Guo X, Harada C, Namekata K et al (2010) Delayed onset of experimental autoimmune encephalomyelitis in Olig1 deficient mice. PLoS One 9:e13083. doi:10.1371/journal.pone.0013083
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Japan
About this chapter
Cite this chapter
Guo, X. (2014). Optic Neuritis. In: Nakazawa, T., Kitaoka, Y., Harada, T. (eds) Neuroprotection and Neuroregeneration for Retinal Diseases. Springer, Tokyo. https://doi.org/10.1007/978-4-431-54965-9_21
Download citation
DOI: https://doi.org/10.1007/978-4-431-54965-9_21
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-54964-2
Online ISBN: 978-4-431-54965-9
eBook Packages: MedicineMedicine (R0)